Similarly, a combination of anti-IGF-1R and SRC therapies displayed enhanced antitumour activity in in vitro and in vivo models of rhabdomyosarcoma when compared to either drug alone [47]. The gene discussed is IGF1R; the disease is rhabdomyosarcoma.